CSPC Pharmaceutical Group (HKEX: 01093) and AstraZeneca will establish a biologics manufacturing joint venture in China, expanding a partnership that has already generated more than USD 20 billion in potential deal value across multiple licensing agreements this year. According to a CSPC announcement, the two firms have signed a JV contract to construct and operate a new-generation biologics manufacturing facility in Shijiazhuang, China.
CSPC will hold a 51% equity stake and contribute its AI-driven current good manufacturing practice (cGMP) system and facility construction expertise; AstraZeneca will hold 49% and contribute global quality standards oversight and supply chain management capabilities. The JV's initial scope covers the manufacture and supply of mutually agreed biologics drug substances for global markets, with both parties retaining the option to incorporate additional products as capacity scales. No specific biologic programs or drug candidates are named in the agreement.
The facility is described as a next-generation biologics drug substance manufacturing platform combining CSPC's automated, intelligent, and lean manufacturing systems with AstraZeneca's global quality framework. CSPC's manufacturing contribution is characterized by the company as an AI-integrated cGMP operating model applied to biologics upstream and downstream processing. The JV contract remains subject to customary closing conditions, including regulatory approvals. No financial terms were disclosed.